LONDON, Sept. 25, 2020 /PRNewswire/ -- Takeda UK Ltd. is pleased to announce that following a review meeting in July 2020, the NHS England Clinical Priorities Advisory Group (CPAG) has provided a positive recommendation for the routine commissioning of VEYVONDI®?(vonicog alfa), the first and only recombinant von Willebrand factor (VWF) treatment for adults with von Willebrand disease (VWD).[2]
Baxalta's Veyvondi (vonicog alfa) Receives Approval in Europe
European regulators have approved Shire’s von Willebrand Disease therapy Veyvondi.
Market Place
Share
Share
